Navigation Links
Promising and perilous? The ambivalent role of the CXCL12/ CXCR4 axis in heart repair
Date:11/30/2011

The chemokine CXCL12 acts as a chemical signal which mobilizes hematopoietic and other types of stem cells to leave the bone marrow and enter the circulation. Secretion of CXCL12 also guides these cells to sites at which the perfusion of tissue is sub-optimal due to localized obstruction of blood flow. These capabilities have made CXCL12 and its cognate receptor CXCR4 interesting candidates for therapies aimed at mitigating the effects of damage to the heart caused by myocardial infarction.

A team of researchers led by Professor Christian Weber of the Medical Center of the University of Munich has now taken a closer look at the normal physiological function of this ligand-receptor couple. Their results reveal that the molecules have "rather ambivalent roles," as Weber puts it.

Myocardial infarction remains one of the leading causes of death in Western societies. The condition occurs when parts of the heart muscle can no longer be adequately supplied with oxygen because blood flow through the coronary arteries is impeded. Researchers have therefore suggested that CXCL12 and CXCR4 could perhaps be used therapeutically to direct stem cells required for the formation of new blood vessels to migrate into ischemic, i.e. poorly perfused, tissues and thus help to increase blood flow in such areas.

"The precise physiological functions of the chemokine and its receptor are poorly understood, although these are the crucial determinants of their therapeutic potential and of possible side-effects," Weber points out. "We therefore studied the effects of infarction in an animal model in which the amount of CXCR4 produced is specifically reduced. We focused on the molecular and cellular consequences of infarction, particularly with respect to the recovery of cardiac function, formation of scar tissue, severity of inflammation, and neovascularization of heart muscle."

To their surprise the researchers found that reduction of the CXCR4 level correlated with significant reductions in infarct size and the degree of tissue inflammation, but that recovery of blood flow and neovascularization were concomitantly decreased. These opposing effects together meant that heart function was equally impaired whether or not the level of CXCR4 function was reduced.

"However, we did see some evidence for an improvement in adaptation to sub-optimal levels of oxygen," Weber remarks. "Although we cannot assume that these results are immediately applicable to the human heart, they do point toward the possibility especially in the case of systemic therapy of quite critical side-effects. We should perhaps focus on more localized approaches, such as the direct injection of stem cells with higher levels of CXCR4, or of CXCL12 variants that remain confined to the damaged areas of the heart or retain their activity in the coronary arteries for longer." (suwe/PH)


'/>"/>

Contact: Luise Dirscherl
dirscherl@lmu.de
49-892-180-2706
Ludwig-Maximilians-Universitt Mnchen
Source:Eurekalert

Related medicine news :

1. New artemisinin-based treatment against malaria promising
2. New Multiple Sclerosis Therapy Promising in Early Trial
3. Promising Malaria Vaccine May Save Childrens Lives
4. Promising new approach to treating debilitating nervous system disease
5. FDG-PET appears promising for predicting prognosis of patients with inoperable NSCLC
6. New half-match bone marrow transplant procedure yields promising outcomes for cancer patients
7. DOE laboratories help develop promising new cancer fighting drug, vemurafenib
8. Experimental Drug Promising Against Tough-to-Treat Asthma
9. INFORMS: CARE positions disaster relief with promising discipline of humanitarian logistics
10. Massachusetts General Hospital, Iacocca Foundation announce promising results of Phase I diabetes trial
11. Fighting cancer with cancer: Mayo Clinic finds promising use for thyroid cancer gene
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, ... organization dedicated to helping service members that have been wounded in battle and their ...
(Date:6/24/2016)... Knoxville, TN (PRWEB) , ... June 24, 2016 ... ... develop population health management skills and infrastructure. Most providers, however, are unsure how ... Population Health Ascend to define a path forward tailored to an ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Dr. Seema Daulat, ... Evans Dermatology in the South Lamar location as of July 13, 2016. , Dr. ... School. As a medical student, she regularly volunteered at the Agape Clinic serving Dallas’ ...
(Date:6/23/2016)... ... June 23, 2016 , ... The Mechille Wilson Agency, ... throughout Jasper County and the surrounding region, is initiating a charity drive to assist ... raise funds earmarked for a scholarship fund that will be presented to the chosen ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
Breaking Medicine Technology: